MacuLogix is seeking the funding for its macular degeneration early-detection tool.
More Articles on Ophthalmology:
Dr. Mary Green Honored as Sightpath Top Surgeon
Experimental Bausch + Lomb Glaucoma Treatment Proves Effective
National Eye Institute Funds $6.2M Macular Degeneration Study
MacuLogix Seeks $5M of Series B Funds
MacuLogix, an ophthalmic diagnostics company based in Hummelstown, Pa., has announced it is aiming to raise $5 million in Series B funding, according to a DOWJONES report.
